Multiple Treatment of Triple-Negative Breast Cancer Through Gambogic Acid-Loaded Mesoporous Polydopamine
Jiaqi Liu
Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072 China
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610064 China
Search for more papers by this authorHongmei Liu
Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072 China
Search for more papers by this authorShan Huang
Cancer Center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072 China
Search for more papers by this authorHong Peng
Institute of Fundamental and Frontier Science, University of Electronic Science and Technology of China, Chengdu, 610054 China
Search for more papers by this authorJiamei Li
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610064 China
Search for more papers by this authorKerong Tu
Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072 China
Search for more papers by this authorSumin Tan
Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072 China
Wenjiang District People's Hospital of Chengdu, Chengdu, 611130 China
Search for more papers by this authorRou Xie
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610064 China
Search for more papers by this authorLei Lei
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610064 China
Search for more papers by this authorCorresponding Author
Qin Yue
Institute of Fundamental and Frontier Science, University of Electronic Science and Technology of China, Chengdu, 610054 China
E-mail: [email protected]; [email protected]; [email protected]
Search for more papers by this authorCorresponding Author
Huile Gao
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610064 China
E-mail: [email protected]; [email protected]; [email protected]
Search for more papers by this authorCorresponding Author
Lulu Cai
Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072 China
E-mail: [email protected]; [email protected]; [email protected]
Search for more papers by this authorJiaqi Liu
Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072 China
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610064 China
Search for more papers by this authorHongmei Liu
Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072 China
Search for more papers by this authorShan Huang
Cancer Center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072 China
Search for more papers by this authorHong Peng
Institute of Fundamental and Frontier Science, University of Electronic Science and Technology of China, Chengdu, 610054 China
Search for more papers by this authorJiamei Li
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610064 China
Search for more papers by this authorKerong Tu
Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072 China
Search for more papers by this authorSumin Tan
Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072 China
Wenjiang District People's Hospital of Chengdu, Chengdu, 611130 China
Search for more papers by this authorRou Xie
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610064 China
Search for more papers by this authorLei Lei
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610064 China
Search for more papers by this authorCorresponding Author
Qin Yue
Institute of Fundamental and Frontier Science, University of Electronic Science and Technology of China, Chengdu, 610054 China
E-mail: [email protected]; [email protected]; [email protected]
Search for more papers by this authorCorresponding Author
Huile Gao
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610064 China
E-mail: [email protected]; [email protected]; [email protected]
Search for more papers by this authorCorresponding Author
Lulu Cai
Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072 China
E-mail: [email protected]; [email protected]; [email protected]
Search for more papers by this authorAbstract
Triple-negative breast cancer (TNBC) is a highly heterogeneous subtype of breast cancer, characterized by aggressiveness and high recurrence rate. As monotherapy provides limited benefit to TNBC patients, combination therapy emerges as a promising treatment approach. Gambogic acid (GA) is an exceedingly promising anticancer agent. Nonetheless, its application potential is hampered by low drug loading efficiency and associated toxic side effects. To overcome these limitations, using mesoporous polydopamine (MPDA) endowed with photothermal conversion capabilities is considered as a delivery vehicle for GA. Meanwhile, GA can inhibit the activity of heat shock protein 90 (HSP90) to enhance the photothermal effect. Herein, GA-loaded MPDA nanoparticles (GA@MPDA NPs) are developed with a high drug loading rate of 75.96% and remarkable photothermal conversion performance. GA@MPDA NPs combined with photothermal treatment (PTT) significantly inhibit the tumor growth, and effectively trigger the immunogenic cell death (ICD), which thereby increase the number of activated effector T cells (CD8+ T cells and CD4+ T cells) in the tumor, and hoist the level of immune-inflammatory cytokines (IFN-γ, IL-6, and TNF-α). The above results suggest that the combination of GA@MPDA NPs with PTT expected to activate the antitumor immune response, thus potentially enhancing the clinical therapeutic effect on TNBC.
Conflict of Interest
The authors declare no conflict of interest.
Open Research
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Supporting Information
| Filename | Description |
|---|---|
| smll202309583-sup-0001-SuppMat.pdf410.3 KB | Supporting Information |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray, CA Cancer J Clin 2021, 71, 209.
- 2K. Asleh, N. Riaz, T. O. Nielsen, J Exp Clin Cancer Res 2022, 41, 265.
- 3J. Y. So, J. Ohm, S. Lipkowitz, L. Yang, Pharmacol. Ther. 2022, 237, 108253.
- 4a) L. Zhao, X. Zhang, X. Wang, X. Guan, W. Zhan, J. J. Ma, Nanobiotechnology 2021, 19, 335; b) X. Li, J. F. Lovell, J. Yoon, X. Chen, Nat. Rev. Clin. Oncol. 2020, 17, 657; c) Z. Yuan, C. Lin, Y. He, B. Tao, M. Chen, J. Zhang, P. Liu, ACS Nano 2020, 14, 3546.
- 5D. Zhi, T. Yang, J. O'Hagan, S. Zhang, R. F. Donnelly, J. Control. Release 2020, 325, 52.
- 6X. Dai, X. Zhao, Y. Liu, B. Chen, X. Ding, N. Zhao, F. J. Xu, Small 2021, 17, e2006004.
- 7Y. Huang, G. Zeng, Q. Xin, J. Yang, C. Zeng, K. Tang, S. T. Yang, MedComm 2020, 1, 202.
- 8A. Maleki, J. He, S. Bochani, V. Nosrati, M. A. Shahbazi, B. Guo, ACS Nano 2021, 15, 18895.
- 9a) W. Cheng, X. Zeng, H. Chen, Z. Li, W. Zeng, L. Mei, Y. Zhao, ACS Nano 2019, 13, 8537; b) Y. Liu, D. Xu, Y. Liu, X. Zheng, J. Zang, W. Ye, Y. Zhao, R. He, S. Ruan, T. Zhang, H. Dong, Y. Li, Biomaterials 2022, 284, 121516.
- 10L. Wang, Y. He, T. He, G. Liu, C. Lin, Li K., L. Lu, K. Cai, Biomaterials 2020, 255, 120208.
- 11X. Wang, T. Yang, Z. Yu, T. Liu, R. Jin, L. Weng, Y. Bai, J. J. Gooding, Y. Zhang, X. Chen, Adv. Mater. 2022, 34, 2110219.
- 12M. Wang, M. Chang, P. Zheng, Q. Sun, G. Wang, J. Lin, C. Li, Adv. Sci. 2022, 9, e2202332.
- 13G. Zhang, W. Cheng, L. Du, C. Xu, J. Li, J. Nanobiotechnol. 2021, 19, 9.
- 14a) G. Gao, Y. W. Jiang, Y. Guo, H. R. Jia, X. T. Cheng, Y. Deng, X. Wang, Y. X. Zhu, H. Y. Guo, W. Sun, X. Y. Liu, J. Zhao, S. Yang, Z. W. Yu, Raya, F. M. S., G. L. Liang, F. G. Wu, Adv. Funct. Mater. 2020, 30, 1909391; b) T. Costa, N. M. Raghavendra, C. Penido, Eur. J. Med. Chem. 2020, 189, 112063.
- 15a) S. Lyu, X. Zhang, Z. Tu, H. Zhou, X. Ke, Y. Qu, Pharmacol. Res. 2022, 182, 106279; b) E. Hatami, M. Jaggi, S. C. Chauhan, M. M. Yallapu, Biochim. Biophys. Acta Rev. Cancer 2020, 1874, 188381.
- 16Z. Li, X. Lai, S. Fu, L. Ren, H. Cai, H. Zhang, Z. Gu, X. Ma, K. Luo, Adv. Sci. 2022, 9, e2201734.
- 17Z. Jing, Q. Du, X. Zhang, Y. Zhang, Chem. Eng. J. 2022, 446, 137147.
- 18X. Chen, D. R. Chen, H. Liu, L. Yang, Y. Zhang, L. L. Bu, Z. J. Sun, L. Cai, J. Control. Release 2022, 351, 381.
- 19a) B. Zhuang, T. Chen, Y. Huang, Z. Xiao, Y. Jin, Acta Pharm. Sin. B 2022, 12, 1447; b) T. Chen, B. Zhuang, Y. Huang, Y. Liu, B. Yuan, W. Wang, T. Y. Yuan, L. N. Du, Y. G. Jin, Acta Pharm. Sin. B 2022, 12, 2522; c) L. Lin, H. Li, Z. Chen, X. Wen, R. Yan, L. Liu, C. H. Tao, J. Drug Deliv. Sci. Technol. 2022, 76, 103819.
- 20a) M. Aioub, S. R. Panikkanvalappil, M. A. El-Sayed, ACS Nano 2017, 11, 579; b) I. B. Slimen, T. Najar, A. Ghram, H. Dabbebi, M. Ben Mrad, M. Abdrabbah, Int. J. Hyperthermia 2014, 30, 513; c) L. Minai, D. Yeheskely-Hayon, D. Yelin, Sci. Rep. 2013, 3, 2146; d) H. Fukumura, M. Sato, K. Kezuka, I. Sato, X. Feng, S. Okumura, J. T. Fu, U. Yokoyama, H. Eguchi, Y. Ishikawa, T. Saito, J. Physiol. Sci. 2012, 62, 251.
- 21D. Chen, J. Zhang, Y. Tang, X. Huang, J. Shao, W. Si, J. Ji, Q. Zhang, W. Huang, X. Dong, J. Mater. Chem. B 2018, 6, 4522.
- 22a) Q. Li, Z. Shi, F. Zhang, W. Zeng, D. Zhu, L. Mei, Acta Pharm. Sin. B 2022, 12, 107; b) A. Ahmed, S. W. G. Tait, Mol. Oncol. 2020, 14, 2994.
- 23a) D. Zheng, J. Liu, L. Xie, Y. Wang, Y. Ding, R. Peng, M. Cui, L. Wang, Y. G. Zhang, C. Q. Zhang, Z. M. Yang, Acta Pharm. Sin. B 2022, 12, 2740; b) X. Liu, S. Liang, X. Sang, L. Chang, S. Fu, H. Yang, H. Z. Yang, Y. J. Liu, N. Zhang, Acta Pharm. Sin. B 2023, 13, 1740.
- 24A. A. Sousa-Junior, F. Mello-Andrade, J. V. R. Rocha, T. G. Hayasaki, J. S. de Curcio, L. D. C. Silva, R. C. de Santana, E. Martins Lima, C. G. Cardoso, E. P. Silveira-Lacerda, S. A. Mendanha, A. F. Bakuzis, Pharmaceutics 2023, 15, 943.
- 25J. Jiang, M. Feng, A. Jacob, L. Z. Li, H. N. Xu, Adv. Exp. Med. Biol. 2021, 1269, 253.
- 26B. Lim, G. N. Hortobagyi, Cancer Metast. Rev. 2016, 35, 495.
- 27Y. Li, H. Zhang, Y. Merkher, L. Chen, N. Liu, S. Leonov, Y. Chen, J. Hematol. Oncol. 2022, 15, 121.
- 28F. Borri, A. Granaglia, Semin. Cancer Biol. 2021, 72, 136.
- 29S. Zhu, Y. Wu, B. Song, M. Yi, Y. Yan, Q. Mei, K. Wu, J. Hematol. Oncol. 2023, 16, 100.
- 30G. Gao, X. Sun, G. Lian, Adv. Funct. Mater. 2021, 31, 2100738.
- 31Y. Xi, L. Chen, J. Tang, B. Yu, W. Shen, X. Niu, Immunol Rev 2023, 321, 94.
